The generic name for Tavneos is avacopan [1].
What is avacopan used for?
Avacopan is used to treat adult patients with severe active ANCA-associated vasculitis (AAV) [1]. ANCA-associated vasculitis is a serious autoimmune condition that can affect the kidneys, lungs, and other organs [1].
How does avacopan work?
Avacopan is a selective C5a receptor inhibitor. It works by blocking the activity of the C5a complement protein, which is involved in the inflammatory process of ANCA-associated vasculitis [1]. By inhibiting the C5a receptor, avacopan helps to reduce inflammation and prevent damage to blood vessels [1].
When was avacopan approved?
Avacopan received its initial approval from the U.S. Food and Drug Administration (FDA) in October 2021 [1].
What are the potential side effects of avacopan?
Common side effects associated with avacopan include headache, nausea, diarrhea, fever, and upper abdominal pain [1].
Are there any safety concerns with avacopan?
One of the significant safety concerns highlighted in clinical trials was a higher incidence of serious infections in patients treated with avacopan compared to those on standard therapy [1].
What is the competition for avacopan?
Prior to the approval of avacopan, standard treatment for severe active ANCA-associated vasculitis typically involved high-dose corticosteroids in combination with an immunosuppressant [1]. Avacopan offers an alternative by allowing for the potential reduction or even avoidance of corticosteroids [1].
Does avacopan have patent protection?
Information regarding the specific patent status and expiry dates for avacopan can be found on DrugPatentWatch.com [2].